专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09205133B2 Therapeutic for treating Clostridium difficile infection 有权
标题翻译：治疗艰难梭菌感染的治疗方法
公开(公告)号：US09205133B2
公开(公告)日：2015-12-08
申请号：US14402389
申请日：2013-05-08
申请人： London School of Hygiene and Tropical Medicine
发明人： Lisa Dawson , Brendan Wren
IPC分类号： A61K38/46 , A61K45/06 , A01N43/90 , C11D3/48 , C11D3/386
CPC分类号： A61K38/465 , A01N43/90 , A61K38/482 , A61K45/06 , A61L2/16 , C11D3/38636 , C11D3/48 , C12Y301/21 , C12Y301/21001 , C12Y301/21002 , C12Y301/22001 , C12Y304/21064
摘要： The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilizing a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilizing product impregnated with or containing at least deoxyribonuclease.
摘要翻译：本发明涉及用于治疗怀疑或存在的艰难梭菌感染的脱氧核糖核酸酶; 至少包含脱氧核糖核酸酶的药物或兽药组合物或制剂，用于治疗怀疑或现存的艰难梭菌感染; 至少包含脱氧核糖核酸酶的组合治疗剂，用于治疗疑似或现存的艰难梭菌感染; 一种治疗怀疑被感染或受到艰难梭菌感染的哺乳动物的方法，包括至少使用脱氧核糖核酸酶; 一种清洁或消毒包含使用至少脱氧核糖核酸酶的材料或产品的方法; 和至少含有脱氧核糖核酸酶或至少含有脱氧核糖核酸酶的清洁或灭菌产品。

2. 发明申请

US20160058846A1 THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION 审中-公开
公开(公告)号：US20160058846A1
公开(公告)日：2016-03-03
申请号：US14932669
申请日：2015-11-04
申请人： London School of Hygiene and Tropical Medicine
发明人： Lisa Dawson , Brendan Wren
IPC分类号： A61K38/46 , C11D3/48 , A61L2/16 , C11D3/386 , A61K45/06 , A61K38/48
CPC分类号： A61K38/465 , A01N43/90 , A61K38/482 , A61K45/06 , A61L2/16 , C11D3/38636 , C11D3/48 , C12Y301/21 , C12Y301/21001 , C12Y301/21002 , C12Y301/22001 , C12Y304/21064
摘要： The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease.

3. 发明授权

US12098215B2 Fusion protein construct 有权
公开(公告)号：US12098215B2
公开(公告)日：2024-09-24
申请号：US16307621
申请日：2017-06-06
申请人： NORTHWESTERN UNIVERSITY
发明人： Milan Mrksich , Justin A. Modica
IPC分类号： C07K16/46 , A61P19/02 , A61P35/00 , A61P37/00 , C07K16/32 , C12N9/18 , A61K39/00
CPC分类号： C07K16/46 , A61P19/02 , A61P35/00 , A61P37/00 , C07K16/32 , C12N9/18 , C12Y301/01074 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/61 , C12Y201/01037 , C12Y301/21002 , C12Y302/01021 , C12Y304/11018 , C12Y304/24024 , C12Y305/02006
摘要： The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the linker includes a first and second functional groups specific for irreversibly inhibiting the first and second fusion protein reactive enzymes. The disclosure further provides a method including (a) contacting a first fusion protein including an affinity reagent and a reactive enzyme with a linker including a functional group specific for irreversibly inhibiting the first fusion protein reactive enzyme thereby coupling the first fusion protein and the linker, and (b) contacting a second fusion protein including an affinity reagent and a reactive enzyme with the linker, the linker including a functional group specific for irreversibly inhibiting the second fusion protein reactive enzyme thereby coupling the second fusion protein and the linker.

4. 发明申请

US20180051341A1 Method for Reducing Sequencing Errors Caused by DNA Fragmentation 审中-公开
公开(公告)号：US20180051341A1
公开(公告)日：2018-02-22
申请号：US15414260
申请日：2017-01-24
申请人： New England Biolabs, Inc.
发明人： Thomas C. Evans, Jr. , Laurence Ettwiller , Lixin Chen , Pingfang Liu
IPC分类号： C12Q1/68
CPC分类号： C12Y605/01001 , C12Q1/6806 , C12Y207/07007 , C12Y301/21002 , C12Y302/02023 , C12Q2521/514 , C12Q2523/301 , C12Q2535/122
摘要： Provided herein, among other things, is a method for reducing sequencing errors caused by mechanical DNA fragmentation. In some embodiments, this method may comprise: (a) obtaining a DNA sample; (b) mechanically fragmenting the DNA sample to produce a template; (c) treating the fragmented DNA with a plurality of DNA repair enzymes; and (d) obtaining a sequence of the fragmented DNA. The treatment step (c) reduces the number of fragmentation induced errors.

5. 发明申请

US20150104489A1 THERAPEUTIC FOR TREATING CLOSTRIDIUM DIFFICILE INFECTION 有权
标题翻译：治疗闭锁性感染的治疗方法
公开(公告)号：US20150104489A1
公开(公告)日：2015-04-16
申请号：US14402389
申请日：2013-05-08
申请人： London School of Hygiene and Tropical Medicine
发明人： Lisa Dawson , Brendan Wren
IPC分类号： A61K38/46 , A61K45/06 , A01N43/90
CPC分类号： A61K38/465 , A01N43/90 , A61K38/482 , A61K45/06 , A61L2/16 , C11D3/38636 , C11D3/48 , C12Y301/21 , C12Y301/21001 , C12Y301/21002 , C12Y301/22001 , C12Y304/21064
摘要： The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilising a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilising product impregnated with or containing at least deoxyribonuclease.
摘要翻译：本发明涉及用于治疗怀疑或存在的艰难梭菌感染的脱氧核糖核酸酶; 至少包含脱氧核糖核酸酶的药物或兽药组合物或制剂，用于治疗怀疑或现存的艰难梭菌感染; 至少包含脱氧核糖核酸酶的组合治疗剂，用于治疗疑似或现存的艰难梭菌感染; 一种治疗怀疑被感染或受到艰难梭菌感染的哺乳动物的方法，包括至少使用脱氧核糖核酸酶; 一种清洁或消毒包含使用至少脱氧核糖核酸酶的材料或产品的方法; 和至少含有脱氧核糖核酸酶或至少含有脱氧核糖核酸酶的清洁或灭菌产品。

6. 发明授权

US5302389A Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease 失效
标题翻译：通过施用T4内切核酸酶治疗UV诱导的接触性超敏反应抑制的方法
公开(公告)号：US5302389A
公开(公告)日：1994-04-12
申请号：US931218
申请日：1992-08-17
申请人： Margaret L. Kripke , Daniel B. Yarosh
发明人： Margaret L. Kripke , Daniel B. Yarosh
IPC分类号： A61K8/14 , A61K8/66 , A61K9/127 , A61K38/46 , A61Q17/04 , A61Q19/00 , A61K37/22 , A61K37/54
CPC分类号： A61K8/66 , A61K38/465 , A61K8/14 , A61K9/1272 , A61Q17/04 , A61Q19/00 , C12Y301/21002
摘要： Exposing the skin to UV radiation interferes with the induction of the T-cell mediated immune response, including both delayed (DHS) and contact (CHS) hyper-sensitivity immune responses initiated at non-irradiated sites. The present inventors have discovered that DNA is at least one of the targets for UV-induced hypersensitivity, and demonstrate that the application of DNA repair enzymes can reverse the damaging effects of UV irradiation on both the DHS and CHS response. The usefulness of the invention in this regard was tested using a model immunosuppression system in mice. In these studies, mice were first exposed to UV radiation and then liposomes were used to deliver a dimer-specific excision repair enzyme to their epidermis in situ. The application of liposomal T4 endonuclease V encapsulated to the UV-irradiated skin both decreased the number of cyclobutane pyrimidine dimers in the epidermis and prevented suppression of both delayed and contact hypersensitivity responses. Moreover, the formation of suppressor lymphoid cells was inhibited. These studies illustrate that the delivery of lesion-specific DNA repair enzymes to living skin after UV irradiation is an effective tool for restoring immune function and suggest that this approach may be broadly applicable to preventing other alterations caused by DNA damage, including preventing or reversing viral activation (e.g., herpes virus activation), oncogene expression, or autoimmune episodes.
摘要翻译：将皮肤暴露于紫外线辐射干扰T细胞介导的免疫应答的诱导，包括在非照射部位发起的延迟（DHS）和接触（CHS）超敏感性免疫应答。本发明人已经发现，DNA是UV诱导的超敏反应的至少一个目标，并且证明DNA修复酶的应用可以逆转UV照射对DHS和CHS响应的破坏作用。使用小鼠中的模型免疫抑制系统测试本发明在这方面的有用性。在这些研究中，首先将小鼠暴露于紫外线辐射，然后使用脂质体将原位二聚体特异性切除修复酶递送至其表皮。脂质体T4内切核酸酶V包封在紫外线照射皮肤上的应用减少了表皮中环丁烷嘧啶二聚体的数量，并阻止了延迟和接触超敏反应的抑制。此外，抑制性淋巴样细胞的形成被抑制。这些研究表明，紫外线照射后病毒特异性DNA修复酶对活体皮肤的传递是恢复免疫功能的有效工具，并表明该方法可广泛适用于预防DNA损伤引起的其他改变，包括预防或逆转病毒激活（例如，疱疹病毒激活），癌基因表达或自身免疫发作。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式